TD Cowen downgraded Verona Pharma (VRNA) to Hold from Buy with a price target of $107, up from $100, after the company entered into an agreement under which Merck (MRK) will acquire it for $107 per American depository share, or $10B. TD does not expect regulatory concerns or additional takeover offers. As such, the deal should close in Q4 with no other major catalysts in the interim, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz
- Verona Pharma downgraded to Hold from Buy at Canaccord
- Verona Pharma downgraded to Hold from Buy at Jefferies
- Video: Verona Pharma jumps after agreeing to be acquired by Merck for $10B
- Morning Movers: Starbucks climbs following reports of interest in China business